Abel Hall LLC Has $517,000 Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Abel Hall LLC increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 3.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 6,013 shares of the company’s stock after buying an additional 206 shares during the quarter. Abel Hall LLC’s holdings in Novo Nordisk A/S were worth $517,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. Xponance Inc. increased its holdings in shares of Novo Nordisk A/S by 27.6% during the second quarter. Xponance Inc. now owns 2,665 shares of the company’s stock worth $380,000 after buying an additional 576 shares in the last quarter. AQR Capital Management LLC raised its position in Novo Nordisk A/S by 110.5% in the second quarter. AQR Capital Management LLC now owns 17,164 shares of the company’s stock valued at $2,450,000 after purchasing an additional 9,012 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Novo Nordisk A/S by 2.2% during the second quarter. The Manufacturers Life Insurance Company now owns 131,876 shares of the company’s stock valued at $18,824,000 after purchasing an additional 2,817 shares in the last quarter. Cetera Investment Advisers grew its holdings in shares of Novo Nordisk A/S by 9.5% during the second quarter. Cetera Investment Advisers now owns 290,845 shares of the company’s stock worth $41,515,000 after purchasing an additional 25,307 shares during the last quarter. Finally, New Century Financial Group LLC acquired a new position in shares of Novo Nordisk A/S in the second quarter valued at approximately $247,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $84.05 on Thursday. The company has a market cap of $377.17 billion, a P/E ratio of 27.20, a PEG ratio of 0.90 and a beta of 0.45. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The business has a 50-day moving average price of $94.75 and a two-hundred day moving average price of $114.02. Novo Nordisk A/S has a 1-year low of $78.17 and a 1-year high of $148.15.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on NVO shares. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Finally, BMO Capital Markets cut their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.